Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance <i>In Vivo</i>

3 May 2012

Abstract excerpt

Mutations at amino acids 143, 148, and 155 in HIV-1 integrase (IN) define primary resistance pathways in subjects failing raltegravir (RAL)-containing treatments. Although each pathway appears to be genetically distinct, shifts in the predominant resistant virus population have been reported under continued drug pressure. To better understand this dynamic, we characterized the RAL susceptibility of 200 resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22553340
DOI: 10.1128/jvi.06618-11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance <i>In Vivo</i>PMID 22553340Read ↗

Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to ElvitegravirSemantic proximity Read ↗

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.Semantic proximity Read ↗

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme FunctionsSemantic proximity Read ↗

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.Semantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.Semantic proximity Read ↗

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutationSemantic proximity Read ↗

Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.Semantic proximity Read ↗

Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.